Human Rotavirus Vaccine Market Quadruples by 2023 at a ~11.2% of Whooping CAGR; Asserts MRFR

By , in PR PR Health on .

Pune, India — 12/20/2017 — The Global Human Rotavirus Vaccine Market report titled “Human Rotavirus Vaccine Market Research Report-Forecast to 2023? is a specialist investigation report by Market Research Future includes broad essential research alongside the definite examination of subjective and additionally quantitative perspectives by different industry specialists, key sentiment pioneers to pick up a more profound understanding of the market and industry execution.

Market Research Future published new report, titled “Human Rotavirus Vaccine Market -Research Report: Global Forecast to 2023”.

Some of Key Players profiled in the report are Bharat Biotech, Merck & Co., Inc., GlaxoSmithKline plc., Multinational pharmaceutical drug company and others.

Global Human Rotavirus Vaccine Market – Overview:

Rotavirus vaccine is used to protect against rotavirus infections which cause severe diarrhoea among young children. Symptoms of rotavirus infection include severe diarrhoea, vomiting, fever, and abdominal pain which can result in disease. The global human rotavirus vaccine market is expected to reach US$ 12.3 billion by 2023, and the market is projected to grow at a CAGR of ~ 11.2 % during the forecast period 2017-2023. The major factors influencing the growth of the market include increasing government initiatives and funding for research and development, increasing biopharmaceutical and biotechnology industries, increasing incidence of various diseases in childrens, and growing government focus on prevention of diseases. According to the study by National Center for Biotechnology Information, in 2015 rotavirus related diarrhoea was responsible for killing about 600,000 children. According to the same study it was also been found that more than 80% of all rotavirus-related deaths occurred in in South Asia and sub-Saharan Africa. Across the globe, rotavirus-related deaths denote for approximately 5% of the deaths in children more than 5 years of age. Most of the children are infected with rotavirus at least once by the age of five across the globe. Initiatives have been taken by the World Health Organization (WHO) and has suggested that rotavirus vaccine to be included in national routine vaccinations programs. The consumptions of these vaccines would be responsible to prevent 15 to 34% of severe diarrhoea in the developing countries and 37 to 96% of severe diarrhoea in the developed nations. The results of these vaccines were to be seen in Mexico. According to World Health Organization (WHO) a decline of up to 50% in diarrhoeal deaths in children less than 5 years of age was attributed directly to the use of the vaccine in the country. The development of these vaccines is significantly impacting and showing positive results, due to which there is huge demand of these vaccines and positively impacting the growth of the market. Moreover there is a huge opportunity in developing countries that is grabbed by various market players for expanding their presence in the region. The market is forecasted to demonstrate a double digit growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period 2017 – 2023.

Global Human Rotavirus Vaccine Market – Competitive Analysis:

There are majorly three pharmaceutical companies licensed for rotavirus vaccines, Rotarix that is manufactured by GlaxoSmithKline Biologicals and RotaTeq manufactured by Merck & Co. Inc., a U.S. based company challenging these two major companies an Indian pharmaceutical company Bharat Biotech launched the lowest price rotavirus vaccine named Rotavac. There are various companies are seeking interest in manufacturing of these vaccine due low presence of manufacturers. New necessities for the development, manufacturing and licensure of new vaccine candidates have caused a marked rise in manufacturers' investment costs. To compensate these investments in research and development and engender profits while the manufacturer monopolizes the market.

The company GlaxoSmithKline has offered to deliver this vaccine at price of US$ 2.50 every dose, which creates a 67% decrease over the lowest public price now available. Merck & Co. Inc. has offered to deliver the vaccine at price of US$ 3.5 every dose once the volume of purchase reaches 30 million doses. Although in 2011 there Indian company Bharat Biotech, announced the cost of its vaccine challenging GSK, Merck in the market. With its product Rotavac vaccine, the company quoted the lowest price i.e. 60 rupees that is less than 1$ for three doses of rotavirus vaccine.

The successful launch of this products by Bharat Biotech brought an end to the products research and development since 1985. The company with the help of various institutes like PATH, NIH, CDC and the Stanford University School of Medicine made it possible for the successfully launch of the product. In 2015 the company raised a fund of about $20 million for constructing new facilities and supporting infrastructure at its Genome Valley plant. With this development in its infrastructure the company is expected to generate a capacity of 300 million doses every year. Due to this developments the company lead the market in India and gradually across the world.

Bharat Biotech (India), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc. (Belgium), are the prominent players at the forefront of competition in the Global Human rotavirus vaccine Market and are profiled in MRFR Analysis.


Global Human Rotavirus Vaccine Market – Regional Analysis

The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new technology in the US drives the global human rotavirus vaccine market. Also, concentration of major research companies and vaccine research sector in the developed countries of this region is adding fuel to the market growth.

Europe is the second largest market in the world due to high income and healthcare penetration.

Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector during the forecast period.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.

Market Segmentation:

The global Human rotavirus vaccine market has been segmented on the basis of type and end users.

Based on type, the market has been segmented as Rotarix, RotaTeq, Rotavac, Rotavin-M1, Lanzhou lamb and others.

Based on the end users, the market has been segmented as hospitals & clinics, academic and research and others.


Chapter 1. Introduction

Chapter 2. Research Methodology

Chapter 3. Market Dynamics

Chapter 4. Market Factor Analysis

Chapter 5. Global Human Rotavirus Vaccine Market, By Type

Chapter 6. Global Human Rotavirus Vaccine Market, By End Users

Chapter 7. Global Human Rotavirus Vaccine Market, By Region

Chapter 8. Competitive Landscape

Chapter 9. Company Profile

Chapter 10. Conclusion

Chapter 11. Appendix



About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Akash Anand,
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: [email protected]

The following two tabs change content below.
Brad Bennett

Brad Bennett

Brad grew up in a small town in northern Iowa. He studied chemistry in college, graduated, and married his wife one month later. They were then blessed with two baby boys within the first four years of marriage. Having babies gave their family a desire to return to the old paths – to nourish their family with traditional, homegrown foods; rid their home of toxic chemicals and petroleum products; and give their boys a chance to know a simple, sustainable way of life. They are currently building a homestead from scratch on two little acres in central Texas. There’s a lot to be done to become somewhat self-sufficient, but they are debt-free and get to spend their days living this simple, good life together with their five young children.
%d bloggers like this: